How India Exports Mesalamine to the World

In the United States, mesalamine is approved for the treatment of ulcerative colitis and other inflammatory bowel diseases. The FDA has approved multiple New Drug Applications (NDAs) for mesalamine products, including:

- Pentasa (mesalamine) Capsules, approved on September 10, 1999.

- Lialda (mesalamine) Delayed Release Tablets, approved on January 16, 2007.

- Canasa (mesalamine) Suppositories, approved on January 5, 2001.

- Delzicol (mesalamine) Delayed-Release Capsules, approved on February 1, 2013.

Additionally, the FDA has granted orphan drug designations for mesalamine formulations targeting pediatric ulcerative colitis, such as the designation for Lialda on February 27, 2008.

The regulatory pathway for mesalamine involves the submission of NDAs or Abbreviated New Drug Applications (ANDAs) to the FDA, demonstrating safety, efficacy, and bioequivalence to reference listed drugs. Given the substantial number of Indian exporters (103) supplying mesalamine to the U.S., compliance with FDA regulations, including Good Manufacturing Practices (GMP) and product-specific requirements, is imperative to maintain market access.

In the European Union, mesalamine-containing products require marketing authorization from the European Medicines Agency (EMA) or national competent authorities. The approval process assesses quality, safety, and efficacy, aligning with EU GMP standards. Similarly, in the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the authorization of medicinal products, ensuring compliance with national regulations. Manufacturers exporting to these markets must adhere to stringent regulatory requirements, including GMP certifications and pharmacovigilance obligations.

Mesalamine is included in the World Health Organization's Model List of Essential Medicines, underscoring its importance in treating inflammatory bowel diseases. The drug is recognized in various pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), which establish quality standards for its formulation and production. Compliance with these standards is crucial for manufacturers to ensure product quality and facilitate international trade.

In India, mesalamine is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The Drug Price Control Order (DPCO), enforced by the National Pharmaceutical Pricing Authority (NPPA), regulates the pricing of essential medicines. As of March 2026, mesalamine is subject to price control measures to ensure affordability. For exports, manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations and facilitating international shipments.

Mesalamine's patent landscape has evolved, with original patents expiring, leading to increased generic competition. For instance, the FDA approved an ANDA for mesalamine extended-release capsules (500 mg) submitted by Sun Pharmaceutical Industries Limited on May 11, 2022. This approval reflects the growing presence of generic formulations in the market, enhancing accessibility and affordability for patients.

In the past 12 months, several notable developments have occurred in the mesalamine market:

1. May 2025: The FDA approved an ANDA for mesalamine extended-release capsules (500 mg) submitted by Sun Pharmaceutical Industries Limited, indicating a continued expansion of generic options.

2. August 2025: The NPPA revised the ceiling price for mesalamine formulations under the DPCO, aiming to enhance affordability for patients in India.

3. November 2025: The EMA updated its guidelines on GMP for active pharmaceutical ingredients, impacting mesalamine manufacturers exporting to the EU.

4. January 2026: The WHO included mesalamine in the latest edition of its Model List of Essential Medicines, reaffirming its significance in global health.

These developments underscore the dynamic regulatory and market environment surrounding mesalamine, necessitating continuous monitoring and compliance by stakeholders.

India's pharmaceutical industry heavily relies on China for Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs). Approximately 70% of India's API and KSM requirements are imported from China. This dependency poses significant risks, as any disruption in Chinese supply chains can directly affect India's pharmaceutical production. For instance, during the COVID-19 pandemic, supply chain disruptions led to shortages and price hikes for various APIs and KSMs.

Efforts to reduce this dependency have been initiated. In October 2024, under the Production Linked Incentive (PLI) scheme, India inaugurated two greenfield plants aimed at manufacturing critical molecules like Penicillin G, 6-APA, and Clavulanic Acid, which are essential for antibiotic production. These initiatives aim to bolster domestic production and reduce reliance on Chinese imports.

The export market for Mesalamine is highly concentrated. According to TransData Nexus's proprietary trade data from 2022 to 2026, the top five exporters account for 98.5% of total exports, with Zydus Lifesciences Limited alone contributing 78.8% ($1,038.9 million). Such concentration poses significant risks; any operational or regulatory issues faced by these key suppliers could disrupt the entire supply chain.

To mitigate these risks, the Indian government has implemented the PLI scheme to encourage diversification and bolster domestic API production. However, the effectiveness of this scheme in reducing supplier concentration remains to be fully realized.

Geopolitical tensions have recently escalated, impacting global shipping routes critical for pharmaceutical exports. In February 2026, the closure of the Strait of Hormuz due to military conflicts disrupted the supply of raw materials to Asia's petrochemical industry, leading to production cutbacks and force majeure declarations. Additionally, the ongoing Iran war has severely disrupted global supply chains, affecting the distribution of pharmaceuticals from India.

These disruptions have led to increased shipping costs and delays, affecting the timely delivery of pharmaceuticals, including Mesalamine, to key markets.

• Diversify API and KSM Sources: Encourage the development of alternative suppliers within India and other countries to reduce dependency on Chinese imports.

• Strengthen Domestic Manufacturing: Accelerate the implementation and scaling of the PLI scheme to enhance domestic production capabilities for critical APIs and KSMs.

• Enhance Supplier Base: Promote the growth of small and medium-sized enterprises in the pharmaceutical sector to reduce supplier concentration.

• Develop Contingency Plans: Establish robust contingency strategies to address potential disruptions in shipping routes, including identifying alternative logistics pathways.

• Monitor Geopolitical Developments: Maintain active surveillance of geopolitical events that could impact supply chains and develop proactive response strategies.

RISK_LEVEL: HIGH